LYDIANT Trademark

Trademark Overview

On Monday, February 13, 2012, a trademark application was filed for LYDIANT with the United States Patent and Trademark Office. The USPTO has given the LYDIANT trademark a serial number of 85541225. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 7, 2015. This trademark is owned by Glaxo Group Limited. The LYDIANT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
lydiant

General Information

Serial Number85541225
Word MarkLYDIANT
Filing DateMonday, February 13, 2012
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 7, 2015
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 12, 2012

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
Translation of Words in MarkThe wording "LYDIANT" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, February 18, 2012
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGreenford, Middlesex UB60NN
GB

Trademark Events

Event DateEvent Description
Tuesday, September 8, 2015ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, September 7, 2015ABANDONMENT - NO USE STATEMENT FILED
Wednesday, January 21, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 20, 2015EXTENSION 5 GRANTED
Thursday, January 15, 2015EXTENSION 5 FILED
Thursday, January 15, 2015TEAS EXTENSION RECEIVED
Saturday, July 19, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 18, 2014EXTENSION 4 GRANTED
Monday, July 14, 2014EXTENSION 4 FILED
Monday, July 14, 2014TEAS EXTENSION RECEIVED
Tuesday, January 28, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 27, 2014EXTENSION 3 GRANTED
Tuesday, January 14, 2014EXTENSION 3 FILED
Tuesday, January 14, 2014TEAS EXTENSION RECEIVED
Friday, August 23, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 22, 2013EXTENSION 2 GRANTED
Tuesday, July 23, 2013EXTENSION 2 FILED
Thursday, August 22, 2013CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, July 23, 2013TEAS EXTENSION RECEIVED
Monday, March 25, 2013APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, March 25, 2013TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, January 5, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 3, 2013EXTENSION 1 GRANTED
Thursday, January 3, 2013EXTENSION 1 FILED
Thursday, January 3, 2013TEAS EXTENSION RECEIVED
Tuesday, August 7, 2012NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 12, 2012OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 12, 2012PUBLISHED FOR OPPOSITION
Wednesday, May 23, 2012NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, May 9, 2012LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, May 8, 2012APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 8, 2012TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 8, 2012CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 19, 2012ASSIGNED TO LIE
Friday, April 13, 2012TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 10, 2012NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 10, 2012NON-FINAL ACTION E-MAILED
Tuesday, April 10, 2012NON-FINAL ACTION WRITTEN
Tuesday, April 10, 2012ASSIGNED TO EXAMINER
Saturday, February 18, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, February 16, 2012NEW APPLICATION ENTERED IN TRAM

Related Keywords

lydiant pharmaceutical treatment disorders preparations substances diseases ophthalmic respiratory hepatological oncological